<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:51:14Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8636627" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8636627</identifier>
        <datestamp>2021-12-03</datestamp>
        <setSpec>scirep</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
              <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
              <journal-title-group>
                <journal-title>Scientific Reports</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2045-2322</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8636627</article-id>
              <article-id pub-id-type="pmcid">PMC8636627</article-id>
              <article-id pub-id-type="pmc-uid">8636627</article-id>
              <article-id pub-id-type="pmid">34853395</article-id>
              <article-id pub-id-type="publisher-id">2679</article-id>
              <article-id pub-id-type="doi">10.1038/s41598-021-02679-0</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Procalcitonin metabolomics in the critically ill reveal relationships between inflammation intensity and energy utilization pathways</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kobayashi</surname>
                    <given-names>Hirotada</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Amrein</surname>
                    <given-names>Karin</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lasky-Su</surname>
                    <given-names>Jessica A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Christopher</surname>
                    <given-names>Kenneth B.</given-names>
                  </name>
                  <address>
                    <email>kbchristopher@bwh.harvard.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Division of Renal Medicine, </institution><institution>Brigham and Women’s Hospital, Harvard Medical School, </institution></institution-wrap>Boston, USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.11598.34</institution-id><institution-id institution-id-type="ISNI">0000 0000 8988 2476</institution-id><institution>Division of Endocrinology and Diabetology, </institution><institution>Medical University of Graz, </institution></institution-wrap>Graz, Austria </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Channing Division of Network Medicine, </institution><institution>Brigham and Women’s Hospital, </institution></institution-wrap>Boston, USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Division of Renal Medicine, </institution><institution>Channing Division of Network Medicine, Brigham and Women’s Hospital, </institution></institution-wrap>75 Francis Street, Boston, MA 02115 USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>1</day>
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>1</day>
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <volume>11</volume>
              <elocation-id>23194</elocation-id>
              <history>
                <date date-type="received">
                  <day>17</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>1</day>
                  <month>10</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2021</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">Procalcitonin is a biomarker of systemic inflammation and may have importance in the immune response. The metabolic response to elevated procalcitonin in critical illness is not known. The response to inflammation is vitally important to understanding metabolism alterations during extreme stress. Our aim was to determine if patients with elevated procalcitonin have differences in the metabolomic response to early critical illness. We performed a metabolomics study of the VITdAL-ICU trial where subjects received high dose vitamin D<sub>3</sub> or placebo. Mixed-effects modeling was used to study changes in metabolites over time relative to procalcitonin levels adjusted for age, Simplified Acute Physiology Score II, admission diagnosis, day 0 25-hydroxyvitamin D level, and the 25-hydroxyvitamin D response to intervention. With elevated procalcitonin, multiple members of the short and medium chain acylcarnitine, dicarboxylate fatty acid, branched-chain amino acid, and pentose phosphate pathway metabolite classes had significantly positive false discovery rate corrected associations. Further, multiple long chain acylcarnitines and lysophosphatidylcholines had significantly negative false discovery rate corrected associations with elevated procalcitonin. Gaussian graphical model analysis revealed functional modules specific to elevated procalcitonin. Our findings show that metabolite differences exist with increased procalcitonin indicating activation of branched chain amino acid dehydrogenase and a metabolic shift.</p>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Bioenergetics</kwd>
                <kwd>Metabolomics</kwd>
                <kwd>Randomized controlled trials</kwd>
                <kwd>Acute inflammation</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>National Institute of Health</institution>
                  </funding-source>
                  <award-id>R01 GM115774</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Christopher</surname>
                      <given-names>Kenneth B.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par2">Procalcitonin is a 116-amino acid polypeptide detectable in the blood of healthy adults that rapidly increases 1000-fold with severe critical illness<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. The release of procalcitonin from parenchymal tissue into circulation is stimulated by microbial toxins and modulated by the immune response<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>. Procalcitonin is a commonly used biomarker of severity of systemic inflammation in infection, sepsis, trauma, surgery, cardiogenic shock, autoimmune disease and severe COVID-19<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>. Although published data suggested that procalcitonin has a greater role in inflammation than previously thought, the metabolic response to procalcitonin has not been evaluated<sup><xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR11">11</xref></sup>. Examining the role of procalcitonin in the metabolic response to inflammation can provide a more nuanced understanding of the immune system during the extreme stress of early critical illness.</p>
              <p id="Par3">Procalcitonin may have a detrimental role in the host response to inflammation in critical illness. Procalcitonin is shown to enhance the inflammatory response and stimulate the surface expression of CD16 on human neutrophils and CD14 on lymphocytes<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. In experimental studies, procalcitonin exposure leads to endothelial barrier function impairment and hepatocyte dysfunction<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. Further, experimental models of sepsis show the presence of procalcitonin worsens illness severity and outcomes<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p>
              <p id="Par4">Metabolomic studies performed on blood collected early in critical illness show a profound disturbance of metabolic homeostasis that reflects illness severity and is predictive of adverse outcomes<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. But such work has not addressed the metabolic response to inflammation<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Therefore, we performed a cohort study on the associations between increased procalcitonin levels and changes in metabolites during critical illness. We used global metabolomic profiling to capture a diverse range of metabolites that are measured in plasma, reflecting multiple metabolism pathways. We hypothesize that there is a specific metabolomic profile that represents a response to elevated procalcitonin in critical illness. We measured the abundance of 983 metabolites from 1187 plasma samples over three time points in 419 critically ill subjects collected during the VITdAL-ICU trial<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. We determined the effect of increased procalcitonin on changes in individual metabolites and metabolic pathways over time. Further, we analyzed grouping of specific functionally related metabolites that change in unison with increased procalcitonin.</p>
            </sec>
            <sec id="Sec2">
              <title>Results</title>
              <p id="Par5">In the analytic cohort (N = 419), we found the median [interquartile range] of procalcitonin at day 0 was 0.66 [0.17, 2.79] µg/L, at day 3 was 0.35 [0.12, 1.43] µg/L and at day 7 was 0.21 [0.09, 0.73] µg/L. Baseline characteristics of the cohort were balanced between subjects grouped by procalcitonin level for age, SAPS II score, 25(OH)D level at day 0, intervention status and the absolute change in 25(OH)D level at day 3. Differences existed with respect to sex, C-reactive protein, Day 0 total bilirubin and creatinine, ICU type, and admission diagnosis category (Table <xref rid="Tab1" ref-type="table">1</xref>, Supplementary Table <xref rid="MOESM2" ref-type="media">S1</xref>). The overall 28-day mortality of the 419 subject analytic cohort was 22.6%.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Analytic cohort characteristics by Day 0 procalcitonin levels.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristic</th><th align="left" colspan="2">Day 0 procalcitonin</th><th align="left" rowspan="2">Total</th><th align="left" rowspan="2">P-value</th></tr><tr><th align="left">&lt; 0.50 µg/L</th><th align="left">≥ 0.50 µg/L</th></tr></thead><tbody><tr><td align="left">No</td><td align="left">180</td><td align="left">239</td><td align="left">419</td><td char="." align="char"/></tr><tr><td align="left">Age years Mean (SD)</td><td align="left">63.1 (15.5)</td><td align="left">65.4 (14.2)</td><td align="left">64.4 (14.8)</td><td char="." align="char">0.11</td></tr><tr><td align="left">Female No. (%)</td><td align="left">76 (42)</td><td align="left">73 (31)</td><td align="left">149 (36)</td><td char="." align="char">0.013</td></tr><tr><td align="left">SAPS II Mean (SD)</td><td align="left">32.3 (16.5)</td><td align="left">34.2 (14.5)</td><td align="left">33.4 (15.4)</td><td char="." align="char">0.22</td></tr><tr><td align="left">C-reactive protein Day 0 Mean (SD)</td><td align="left">87.0 (74.5)</td><td align="left">152.3 (90.8)</td><td align="left">124.2 (90.1)</td><td char="." align="char">&lt; 0.001</td></tr><tr><td align="left">Day 0 25(OH)D Mean (SD)</td><td align="left">14.6 (6.3)</td><td align="left">13.4 (10.4)</td><td align="left">13.9 (8.9)</td><td char="." align="char">0.19</td></tr><tr><td align="left">Vitamin D<sub>3</sub> Intervention No. (%)</td><td align="left">79 (44)</td><td align="left">127 (53)</td><td align="left">205 (49)</td><td char="." align="char">0.061</td></tr><tr><td align="left">Change in 25(OH)D Day 0 to Day 3 Median [IQR]</td><td align="left">2.8 [− 0.4, 25.1]</td><td align="left">3.3 [0.1, 12.2]</td><td align="left">3.1 [0, 16.7]</td><td char="." align="char">0.34</td></tr><tr><td align="left">Total Bilirubin Day 0 Mean (SD)</td><td align="left">0.8 (0.9)</td><td align="left">2.1 (3.3)</td><td align="left">1.6 (2.6)</td><td char="." align="char">&lt; 0.001</td></tr><tr><td align="left">Creatinine Day 0 Mean (SD)</td><td align="left">1.0 (0.7)</td><td align="left">1.7 (1.1)</td><td align="left">1.4 (1.0)</td><td char="." align="char">&lt; 0.001</td></tr><tr><td align="left"><bold>ICU</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">&lt; 0.001</td></tr><tr><td align="left">Anesthesia ICU No. (%)</td><td align="left">27 (15)</td><td align="left">53 (22)</td><td align="left">80 (19)</td><td char="." align="char"/></tr><tr><td align="left">Cardiac surgery ICU No. (%)</td><td align="left">27 (15)</td><td align="left">95 (40)</td><td align="left">122 (29)</td><td char="." align="char"/></tr><tr><td align="left">Medical ICU No. (%)</td><td align="left">29 (16)</td><td align="left">60 (25)</td><td align="left">89 (21)</td><td char="." align="char"/></tr><tr><td align="left">Neurological ICU No. (%)</td><td align="left">88 (49)</td><td align="left">18 (8)</td><td align="left">106 (25)</td><td char="." align="char"/></tr><tr><td align="left">Surgical ICU No. (%)</td><td align="left">9 (5)</td><td align="left">13 (5)</td><td align="left">22 (5)</td><td char="." align="char"/></tr><tr><td align="left">28-day mortality No. (%)</td><td align="left">25 (14)</td><td align="left">70 (29)</td><td align="left">95 (23)</td><td char="." align="char">&lt; 0.001</td></tr></tbody></table></table-wrap></p>
              <sec id="Sec3">
                <title>Single time point data</title>
                <p id="Par6">We utilized mass spectrometry methods by Metabolon, Inc to investigate circulating changes in metabolites associated with increased procalcitonin. In day 0 plasma samples (N = 419), significant crude differences exist in 591 individual metabolites (q-value threshold of 0.05) in subjects with or without procalcitonin ≥ 0.5 μg/L notable for increases of branched-chain amino acids (BCAAs), short and medium chain acylcarnitines, dicarboxylate fatty acid pathways and decreases in long-chain acylcarnitines, lysophosphatidylcholine and sphingomyelin metabolites (Supplementary Data <xref rid="MOESM3" ref-type="media">S1</xref>). Regarding differences in metabolomic profiles of subjects with or without procalcitonin ≥ 0.5 μg/L at day 0, the OPLS-DA model had acceptable predictability (Q2 value 0.427). Confirmation of the stability and robustness of the OPLS-DA model was shown by the permutation test (Q2 intercept of − 0.214, p-value ≤ 0.05) with a negative permutation Q2 intercept indicating model validity (Supplementary Table <xref rid="MOESM2" ref-type="media">S2</xref>). The cross-validation procedure showed that the groups with or without procalcitonin ≥ 0.5 μg/L were significantly separated (CV-ANOVA p-value &lt; 0.001). The ROC analysis showed the predictive ability of the OPLS-DA model was excellent (AUC = 0.92). Further, the model showed good classification performance with 83.1% of cases with procalcitonin ≥ 0.5 μg/L were correctly classified (sensitivity of 85.6%, specificity of 79.8%).</p>
              </sec>
              <sec id="Sec4">
                <title>Multiple time point data</title>
                <p id="Par7">In the repeated measure metabolomics data, mixed-effects modeling of 1187 plasma samples collected at day 0, 3 and 7 from 419 VITdAL-ICU trial subjects (Model 1), 250 metabolites had significantly positive associations with procalcitonin. The metabolites were dominated by increases in BCAAs, short and medium-chain acylcarnitines, dicarboxylate fatty acids, phosphatidylethanolamines, and polyamines (Table <xref rid="Tab2" ref-type="table">2</xref>, Fig. <xref rid="Fig1" ref-type="fig">1</xref>, Supplementary Data <xref rid="MOESM4" ref-type="media">S2</xref>). One-hundred nineteen metabolites had a significant negative association with procalcitonin, including multiple representatives of the lysophosphatidylcholine, and long-chain acylcarnitine pathway metabolites (Table <xref rid="Tab3" ref-type="table">3</xref>, Fig. <xref rid="Fig2" ref-type="fig">2</xref>, Supplementary Data <xref rid="MOESM4" ref-type="media">S2</xref>). The rain plots show highlighted metabolites that are significantly increased (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) or decreased (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) in subjects with increased procalcitonin. Similar metabolite patterns were observed in mixed effects models restricted to the 603 day 0, 3 and 7 samples from 213 subjects who received placebo (Supplementary Data <xref rid="MOESM5" ref-type="media">S3</xref>). A q-value threshold of 0.05 was used to identify all significant mixed effects associations<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Metabolites significantly increased with increased Procalcitonin over days 0–7.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Metabolite</th><th align="left">β coefficient metabolite</th><th align="left">p-value</th><th align="left">− log10p</th><th align="left">q-value</th><th align="left">Super pathway</th><th align="left">Sub pathway</th></tr></thead><tbody><tr><td align="left">3-Hydroxybutyrylcarnitine (C3-DC)</td><td char="." align="char">4.17</td><td align="left">1.19 E−04</td><td char="." align="char">3.92</td><td align="left">6.78 E−04</td><td align="left">Lipid</td><td align="left">Short-chain acylcarnitine</td></tr><tr><td align="left">Succinylcarnitine (C4)</td><td char="." align="char">4.22</td><td align="left">7.58 E−04</td><td char="." align="char">3.12</td><td align="left">3.17 E−03</td><td align="left">Energy</td><td align="left">Short-chain acylcarnitine</td></tr><tr><td align="left">Tiglyl carnitine (C5)</td><td char="." align="char">4.42</td><td align="left">9.86 E−05</td><td char="." align="char">4.01</td><td align="left">5.89 E−04</td><td align="left">Amino acid</td><td align="left">Short-chain acylcarnitine</td></tr><tr><td align="left">2-Methylbutyroylcarnitine (C5)</td><td char="." align="char">3.73</td><td align="left">4.04 E−04</td><td char="." align="char">3.39</td><td align="left">1.86 E−03</td><td align="left">Amino acid</td><td align="left">Short-chain acylcarnitine</td></tr><tr><td align="left">Adipoylcarnitine (C6-DC)</td><td char="." align="char">4.42</td><td align="left">1.50 E−05</td><td char="." align="char">4.82</td><td align="left">1.20 E−04</td><td align="left">Lipid</td><td align="left">Short-chain acylcarnitine</td></tr><tr><td align="left">3-Methyladipoylcarnitine (C7-DC)</td><td char="." align="char">3.08</td><td align="left">4.32 E−03</td><td char="." align="char">2.36</td><td align="left">1.45 E−02</td><td align="left">Lipid</td><td align="left">Short-chain acylcarnitine</td></tr><tr><td align="left">Octanoylcarnitine (C8)</td><td char="." align="char">4.09</td><td align="left">3.83 E−04</td><td char="." align="char">3.42</td><td align="left">1.79 E−03</td><td align="left">Lipid</td><td align="left">Medium-chain acylcarnitine</td></tr><tr><td align="left">Suberoylcarnitine (C8-DC)</td><td char="." align="char">3.19</td><td align="left">5.57 E–−04</td><td char="." align="char">3.25</td><td align="left">2.45 E−03</td><td align="left">Lipid</td><td align="left">Medium-chain acylcarnitine</td></tr><tr><td align="left">cis-4-Decenoylcarnitine (C10:1)</td><td char="." align="char">4.12</td><td align="left">7.12 E−04</td><td char="." align="char">3.15</td><td align="left">2.99 E−03</td><td align="left">Lipid</td><td align="left">Medium-chain acylcarnitine</td></tr><tr><td align="left">Decanoylcarnitine (C10)</td><td char="." align="char">3.94</td><td align="left">6.74 E−04</td><td char="." align="char">3.17</td><td align="left">2.86 E−03</td><td align="left">Lipid</td><td align="left">Medium-chain Acylcarnitine</td></tr><tr><td align="left">3-Methyladipate</td><td char="." align="char">5.74</td><td align="left">7.40 E−09</td><td char="." align="char">8.13</td><td align="left">1.91 E−07</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">Adipate</td><td char="." align="char">3.00</td><td align="left">4.31 E−03</td><td char="." align="char">2.37</td><td align="left">1.45 E−02</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">3-Hydroxyadipate<sup>a</sup></td><td char="." align="char">2.91</td><td align="left">1.89 E−03</td><td char="." align="char">2.72</td><td align="left">7.03 E−03</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">2-Hydroxyadipate</td><td char="." align="char">2.77</td><td align="left">3.30 E−03</td><td char="." align="char">2.48</td><td align="left">1.15 E−02</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">heptenedioate (C7:1-DC)<sup>a</sup></td><td char="." align="char">3.08</td><td align="left">1.83 E−03</td><td char="." align="char">2.74</td><td align="left">6.83 E−03</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">Suberate (C8-DC)</td><td char="." align="char">4.26</td><td align="left">9.47 E−05</td><td char="." align="char">4.02</td><td align="left">5.80 E−04</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">Dodecanedioate (C12)</td><td char="." align="char">3.41</td><td align="left">3.01 E−04</td><td char="." align="char">3.52</td><td align="left">1.46 E–03</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">Dodecenedioate (C12:1-DC)<sup>a</sup></td><td char="." align="char">2.69</td><td align="left">4.47 E−03</td><td char="." align="char">2.35</td><td align="left">1.50 E−02</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">Hexadecanedioate (C16)</td><td char="." align="char">3.43</td><td align="left">2.75 E−04</td><td char="." align="char">3.56</td><td align="left">1.35 E−03</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">Octadecadienedioate (C18:2-DC)<sup>a</sup></td><td char="." align="char">3.81</td><td align="left">2.86 E−04</td><td char="." align="char">3.54</td><td align="left">1.40 E−03</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">Octadecenedioate (C18:1-DC)<sup>a</sup></td><td char="." align="char">3.09</td><td align="left">1.50 E−03</td><td char="." align="char">2.83</td><td align="left">5.82 E−03</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">Octadecanedioate (C18)</td><td char="." align="char">2.51</td><td align="left">7.54 E−03</td><td char="." align="char">2.12</td><td align="left">2.32 E−02</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">Eicosanodioate (C20-DC)</td><td char="." align="char">4.77</td><td align="left">6.57 E−04</td><td char="." align="char">3.18</td><td align="left">2.80 E−03</td><td align="left">Lipid</td><td align="left">Fatty acid, dicarboxylate</td></tr><tr><td align="left">Methylsuccinate</td><td char="." align="char">7.44</td><td align="left">1.87 E−10</td><td char="." align="char">9.73</td><td align="left">8.31 E−09</td><td align="left">Amino acid</td><td align="left">BCAA metabolism</td></tr><tr><td align="left">3-Methylglutaconate</td><td char="." align="char">6.46</td><td align="left">7.79 E−09</td><td char="." align="char">8.11</td><td align="left">1.96 E−07</td><td align="left">Amino acid</td><td align="left">BCAA metabolism</td></tr><tr><td align="left">2,3-Dihydroxy-2-methylbutyrate</td><td char="." align="char">6.44</td><td align="left">2.75 E−09</td><td char="." align="char">8.56</td><td align="left">8.70 E−08</td><td align="left">Amino acid</td><td align="left">BCAA metabolism</td></tr><tr><td align="left">3-Hydroxy-2-ethylpropionate</td><td char="." align="char">5.22</td><td align="left">1.64 E−04</td><td char="." align="char">3.79</td><td align="left">8.72 E−04</td><td align="left">Amino acid</td><td align="left">BCAA metabolism</td></tr><tr><td align="left"><italic>N</italic>-Acetylvaline</td><td char="." align="char">5.19</td><td align="left">6.79 E−04</td><td char="." align="char">3.17</td><td align="left">2.87 E−03</td><td align="left">Amino acid</td><td align="left">BCAA metabolism</td></tr><tr><td align="left">beta-Hydroxyisovalerate</td><td char="." align="char">5.16</td><td align="left">1.30 E−04</td><td char="." align="char">3.89</td><td align="left">7.20 E−04</td><td align="left">Amino acid</td><td align="left">BCAA metabolism</td></tr><tr><td align="left"><italic>N</italic>-Acetylisoleucine</td><td char="." align="char">4.25</td><td align="left">2.35 E−03</td><td char="." align="char">2.63</td><td align="left">8.50 E−03</td><td align="left">Amino acid</td><td align="left">BCAA metabolism</td></tr><tr><td align="left">Ethylmalonate</td><td char="." align="char">4.16</td><td align="left">1.29 E−03</td><td char="." align="char">2.89</td><td align="left">5.21 E−03</td><td align="left">Amino acid</td><td align="left">BCAA metabolism</td></tr><tr><td align="left">Isovalerylglycine</td><td char="." align="char">2.29</td><td align="left">1.52 E−02</td><td char="." align="char">1.82</td><td align="left">4.08 E−02</td><td align="left">Amino acid</td><td align="left">BCAA metabolism</td></tr><tr><td align="left">Sedoheptulose</td><td char="." align="char">4.78</td><td align="left">2.40 E−05</td><td char="." align="char">4.62</td><td align="left">1.83 E−04</td><td align="left">Carbohydrate</td><td align="left">Pentose metabolism</td></tr><tr><td align="left">Arabonate/xylonate</td><td char="." align="char">4.37</td><td align="left">5.22 E−04</td><td char="." align="char">3.28</td><td align="left">2.35 E−03</td><td align="left">Carbohydrate</td><td align="left">Pentose metabolism</td></tr><tr><td align="left">Ribonate</td><td char="." align="char">3.98</td><td align="left">3.03 E−03</td><td char="." align="char">2.52</td><td align="left">1.07 E−02</td><td align="left">Carbohydrate</td><td align="left">Pentose metabolism</td></tr><tr><td align="left">Arabinose</td><td char="." align="char">3.60</td><td align="left">1.31 E−03</td><td char="." align="char">2.88</td><td align="left">5.26 E−03</td><td align="left">Carbohydrate</td><td align="left">Pentose metabolism</td></tr><tr><td align="left">Ribitol</td><td char="." align="char">3.26</td><td align="left">1.30 E−02</td><td char="." align="char">1.89</td><td align="left">3.61 E−02</td><td align="left">Carbohydrate</td><td align="left">Pentose metabolism</td></tr></tbody></table><table-wrap-foot><p>Using repeated measures data (day 0, 3 and 7), the association between relative quantitation of each individual metabolite noted above and Procalcitonin levels over time were determined utilizing linear mixed-effects models correcting for age, sex, baseline 25(OH)D, absolute increase in 25(OH)D, SAPS II, admission diagnosis, plasma day and an individual subject-specific random-intercept. All significant mixed-effects associations have false discovery rate adjusted p-value (q-value) &lt; 0.05. BCAA is Branched-Chain Amino Acids inclusive of Leucine, Isoleucine and Valine. For the Acylcarnitines sub pathway: a capital C is followed by the number of carbons within the fatty acyl group attached to the carnitine. A colon followed by a number is one or more unsaturated carbons in the acylcarnitine ester (i.e. C10:1 is a monounsaturated C10 acylcarnitine). DC following the carbon number is a dicarboxylic acylcarnitine.</p><p><sup>a</sup>Putative identification (Level 2) where predictive or externally acquired structure evidence is present when a reference standard does not exist.</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>Rain plot of metabolites significantly increased with increased Procalcitonin. Repeated measures metabolomics data (day 0, 3 and 7) relative to procalcitonin level. Correlations between procalcitonin levels and individual metabolite abundance at day 0, 3 or 7 were determined utilizing linear regression models correcting for age, sex, SAPS II, admission diagnosis, 25(OH)D at day 0 and for absolute change in 25(OH)D level at day 3. The magnitude of beta coefficient estimates is shown by a color fill scale and the corresponding significance level (− log10(q-value)) is represented by size of the circle. The intensity of the red fill color represents an increase in effect size for that metabolite relative to procalcitonin level. All metabolites shown are significant by a q-value threshold of 0.05. All respective β coefficients and q-values can be found in tabular form in Supplementary Data <xref rid="MOESM5" ref-type="media">S3</xref>. (<bold>A</bold>) Short-chain acylcarnitines (<bold>B</bold>) Medium-chain acylcarnitines (<bold>C</bold>) BCAA metabolites (<bold>D</bold>) Dicarboxylate fatty acids.</p></caption><graphic xlink:href="41598_2021_2679_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Metabolites significantly decreased with increased Procalcitonin over days 0–7.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Metabolite</th><th align="left">β coefficient metabolite</th><th align="left">p-value</th><th align="left">− log10p</th><th align="left">q-value</th><th align="left">Super pathway</th><th align="left">Sub pathway</th></tr></thead><tbody><tr><td align="left">Linolenoylcarnitine (C18:3)*</td><td align="left">− 3.58</td><td align="left">1.65 E−03</td><td align="left">2.78</td><td align="left">6.26 E−03</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">Stearoylcarnitine (C18)</td><td align="left">− 3.68</td><td align="left">5.40 E−03</td><td align="left">2.27</td><td align="left">1.76 E−02</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">Linoleoylcarnitine (C18:2)*</td><td align="left">− 4.16</td><td align="left">9.56 E−04</td><td align="left">3.02</td><td align="left">3.94 E−03</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">Arachidonoylcarnitine (C20:4)</td><td align="left">− 4.41</td><td align="left">1.57 E−04</td><td align="left">3.80</td><td align="left">8.47 E−04</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">Dihomo-linoleoylcarnitine (C20:2)*</td><td align="left">− 3.62</td><td align="left">2.78 E−03</td><td align="left">2.56</td><td align="left">9.98 E−03</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">Dihomo-linolenoylcarnitine (C20:3n3 or 6)*</td><td align="left">− 4.43</td><td align="left">2.13 E−04</td><td align="left">3.67</td><td align="left">1.09 E−03</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">Lignoceroylcarnitine (C24)*</td><td align="left">− 6.03</td><td align="left">3.93 E−05</td><td align="left">4.41</td><td align="left">2.75 E−04</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">Docosapentaenoylcarnitine (C22:5n3)*</td><td align="left">− 2.67</td><td align="left">1.12 E−02</td><td align="left">1.95</td><td align="left">3.25 E−02</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">Adrenoylcarnitine (C22:4)*</td><td align="left">− 2.89</td><td align="left">9.64 E−03</td><td align="left">2.02</td><td align="left">2.84 E−02</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">Docosahexaenoylcarnitine (C22:6)*</td><td align="left">− 3.07</td><td align="left">3.79 E−03</td><td align="left">2.42</td><td align="left">1.29 E−02</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">Cerotoylcarnitine (C26)*</td><td align="left">− 6.43</td><td align="left">3.43 E−06</td><td align="left">5.47</td><td align="left">3.69 E−05</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">Ximenoylcarnitine (C26:1)*</td><td align="left">− 6.92</td><td align="left">1.12 E−07</td><td align="left">6.95</td><td align="left">1.96 E−06</td><td align="left">Lipid</td><td align="left">Long-chain acylcarnitine</td></tr><tr><td align="left">2-Palmitoyl-GPC* (16:0)*</td><td align="left">− 5.86</td><td align="left">8.40 E−06</td><td align="left">5.08</td><td align="left">7.35 E−05</td><td align="left">Lipid</td><td align="left">Lysophosphatidylcholine</td></tr><tr><td align="left">1-Palmitoleoyl-GPC* (16:1)*</td><td align="left">− 5.95</td><td align="left">1.37 E−05</td><td align="left">4.86</td><td align="left">1.12 E−04</td><td align="left">Lipid</td><td align="left">Lysophosphatidylcholine</td></tr><tr><td align="left">1-Palmitoyl-GPC (16:0)</td><td align="left">− 11.80</td><td align="left">6.98 E−11</td><td align="left">10.16</td><td align="left">3.26 E−09</td><td align="left">Lipid</td><td align="left">Lysophosphatidylcholine</td></tr><tr><td align="left">1-Linolenoyl-GPC (18:3)*</td><td align="left">− 3.67</td><td align="left">1.49 E−03</td><td align="left">2.83</td><td align="left">5.82 E−03</td><td align="left">Lipid</td><td align="left">Lysophosphatidylcholine</td></tr><tr><td align="left">1-Linoleoyl-GPC (18:2)</td><td align="left">− 7.97</td><td align="left">6.65 E−07</td><td align="left">6.18</td><td align="left">9.17 E−06</td><td align="left">Lipid</td><td align="left">Lysophosphatidylcholine</td></tr><tr><td align="left">1-Oleoyl-GPC (18:1)</td><td align="left">− 8.74</td><td align="left">2.17 E−07</td><td align="left">6.66</td><td align="left">3.48 E−06</td><td align="left">Lipid</td><td align="left">Lysophosphatidylcholine</td></tr><tr><td align="left">1-Lignoceroyl-GPC (24:0)</td><td align="left">− 6.74</td><td align="left">3.39 E−09</td><td align="left">8.47</td><td align="left">1.02 E−07</td><td align="left">Lipid</td><td align="left">Lysophosphatidylcholine</td></tr></tbody></table><table-wrap-foot><p>Using repeated measures data (day 0, 3 and 7), the association between relative quantitation of each individual metabolite noted above and Procalcitonin levels over time were determined utilizing linear mixed-effects models correcting for age, sex, baseline 25(OH)D, absolute increase in 25(OH)D, SAPS II, admission diagnosis, plasma day and an individual subject-specific random-intercept. All significant mixed-effects associations have false discovery rate adjusted p-value (q-value) &lt; 0.05. For the Acylcarnitines sub pathway: a capital C is followed by the number of carbons within the fatty acyl group attached to the carnitine. A colon followed by a number is one or more unsaturated carbons in the acylcarnitine ester (i.e. C26:1 is a monounsaturated C26 acylcarnitine). GPC is glycerylphosphorylcholine.</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Figure 2</label><caption><p>Rain plot of metabolites significantly decreased with increased Procalcitonin. Correlations between procalcitonin levels and individual metabolite abundance at day 0, 3 or 7 were determined utilizing linear regression models correcting for age, SAPS II, admission diagnosis, 25(OH)D at day 0 and for absolute change in 25(OH)D level at day 3. The magnitude of beta coefficient estimates is shown by a color fill scale and the corresponding significance level (− log<sub>10</sub>(q-value)) is represented by size of the circle. The intensity of the blue fill color represents a decrease in effect size for that metabolite relative to procalcitonin level. All metabolites shown are significant by a q-value threshold of 0.05. All respective β coefficients and q-values can be found in tabular form in Supplementary Data <xref rid="MOESM5" ref-type="media">S3</xref>. (<bold>A</bold>) Lysophosphatidylcholines (<bold>B</bold>) Long chain acylcarnitines.</p></caption><graphic xlink:href="41598_2021_2679_Fig2_HTML" id="MO2"/></fig></p>
              </sec>
              <sec id="Sec5">
                <title>Metabolic networks and mediation</title>
                <p id="Par8">We next explored procalcitonin-specific relationships between metabolites. With Gaussian graphical models (GGMs) we measured pairwise correlations in metabolites that have similar effects. The GGM analyses revealed six procalcitonin-specific functional modules at day 0 (Supplementary Table <xref rid="MOESM2" ref-type="media">S3</xref>). Similar to the mixed effects analyses (Model 1), metabolism of acylcarnitines, polyamines, BCAAs, and dicarboxylate fatty acids are prominently featured in the procalcitonin-specific GGM modules. Metabolites within in each functional module were increased with increased procalcitonin in unison as well as having biological and functional similarity (i.e., in Supplementary Table <xref rid="MOESM2" ref-type="media">S3</xref> Module C, 5 of 6 members are polyamide metabolites).</p>
                <p id="Par9">To determine the potential mediation of the relationship between metabolite abundance and procalcitonin levels we focused on liver function, body mass index and age. Mediation analyses in day 0 data revealed no influence of body mass index or age on associations between procalcitonin levels and all 983 metabolites. With regard to bilirubin, mediation analyses in day 0 data revealed a significant influence on associations between procalcitonin levels and bilirubin of 171 of the 983 individual metabolites (all p-values were &lt; 0.01 and proportion mediated over 10% using 2000 bootstrap samples). One hundred fifty-seven of these mediated metabolites were also identified in our mixed-effects analysis as significantly changed with procalcitonin levels (Supplementary Data <xref rid="MOESM6" ref-type="media">S4</xref>).</p>
                <p id="Par10">Finally, to explore mechanistic insights into our observation of increased BCAA metabolites with increasing procalcitonin, we present unadjusted metabolite abundance data at day 0, 3 and 7 for subjects with procalcitonin &lt; 0.5 μg/L or ≥ 0.5 μg/L (Supplementary Fig. <xref rid="MOESM7" ref-type="media">S1</xref>). Boxplots show relative abundance of plasma BCAAs, branched-chain keto acids, metabolites downstream from branched-chain amino acid dehydrogenase (BCKDH) and BCAA-derived carnitines. The abundance of BCAA metabolites downstream from the BCKDH enzyme complex increase at days 3 and 7 in subjects with procalcitonin ≥ 0.5 μg/L but not with procalcitonin &lt; 0.5 μg/L (Supplementary Fig. <xref rid="MOESM7" ref-type="media">S1</xref>J–T).</p>
              </sec>
            </sec>
            <sec id="Sec6">
              <title>Discussion</title>
              <p id="Par11">The underlying mechanisms of alterations of metabolomic disruption during inflammation remain an enigma. Using multiple analytic approaches, our metabolomics study detected groups of metabolites along similar sub-pathways with strong associations with procalcitonin levels. In the setting of an elevated procalcitonin, our data highlight increases in short-chain acylcarnitines, dicarboxylate fatty acids, phosphatidylethanolamines, and polyamines and decreases in long-chain acylcarnitines, lysophosphatidylcholines, lysoplasmalogens, and sphingomyelins. Further, we illustrate how groups of metabolites with similar procalcitonin associations form modules which may have relevance to the biological interpretation of our metabolomics observations. Our data suggest that knowledge of such patterns and their biological effects are critical for understanding the role of inflammation in general and procalcitonin specifically.</p>
              <p id="Par12">To put our findings into context, the known properties of highlighted metabolites are discussed as a guide for data interpretation. With increased procalcitonin we find metabolic evidence of mitochondrial dysfunction. We find a specific pattern of change in acylcarnitines with increased procalcitonin where short-chain acylcarnitines are elevated and long-chain acylcarnitines are decreased. Primarily released from the liver, plasma short-chain acylcarnitines (C2–C7) are due to incomplete mitochondrial fatty acid β-oxidation and indicative of impaired mitochondrial function<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. We also observe an increase in dicarboxylic fatty acids known to be produced by fatty acid omega oxidation when incomplete fatty acid β-oxidation occurs in the setting of mitochondrial dysfunction<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. The cytochrome P450 (CYP4F) that catalyzes the first step of fatty acid omega oxidation is known to be induced by the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Such circulating dicarboxylic fatty acids are shown to increase in response to starvation and critical illness<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. We additionally note that pentose phosphate pathway metabolites are increased with elevated procalcitonin which suggests a metabolic shift away from fatty acid β-oxidation<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Our observation of increases in plasma short-chain acylcarnitines (C2–C7), dicarboxylic fatty acids and pentose phosphate pathway metabolites with increases in procalcitonin may reflect less efficient fatty acid β-oxidation thorough impaired mitochondrial bioenergetics associated with increased inflammation<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. The mediation of the association between procalcitonin level and metabolite abundance by serum total bilirubin underscores the importance of the liver in metabolism, immunity, inflammation and procalcitonin induction<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>.</p>
              <p id="Par13">Catabolic stress liberates amino acids into the circulation by endogenous protein breakdown including the branched-chain amino acids (BCAA), leucine, isoleucine and valine<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. During inflammation, BCAAs are preferentially transported to the liver over the muscle<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. BCAAs are metabolized to acetyl-CoA or succinyl-CoA when mitochondrial fatty acid β-oxidation is incomplete. The irreversible and rate‐limiting step of BCAA catabolism is the branched‐chain α‐ketoacid dehydrogenase (BCKDH) complex in the mitochondrial matrix<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Experimental animal data show that BCKDH is rapidly activated by acute nutrient deprivation, circulating BCAA excess, exercise, endotoxin, IL-1β and TNFα<sup><xref ref-type="bibr" rid="CR27">27</xref>–<xref ref-type="bibr" rid="CR31">31</xref></sup>. Limited evidence suggests that circulating BCAA excess and mitochondrial BCAA catabolism are measurable in healthy humans under exercise stress and also in the critically ill<sup><xref ref-type="bibr" rid="CR32">32</xref>–<xref ref-type="bibr" rid="CR34">34</xref></sup>.</p>
              <p id="Par14">We observe circulating BCAA catabolic metabolites distal to BCKDH are significantly increased with increasing procalcitonin, suggesting BCKDH activation. Further, we find that short-chain acylcarnitines C3 and C5 are significantly increased with increases in procalcitonin. The C5-acylcarnitines are derived from the BCAA metabolites α-methylbutyryl and isovalerylcarnitine. C3-acylcarnitine is produced from propionyl CoA via catabolism of BCAA, methionine and threonine<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Such increases in circulating C5 and C3 acylcarnitines are shown to occur following BCAA supplementation in ambulatory adults<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. The observed increases of circulating short-chain acylcarnitines, dicarboxylate fatty acids and BCAA catabolic metabolites are all indicative of a metabolic shift. Experimental evidence in healthy humans supports that such a metabolic shift is an adaptive response to endotoxin via alteration of mitochondrial bioenergetics<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>.</p>
              <p id="Par15">We find that higher procalcitonin is associated with increased levels of circulating metabolites of polyamine catabolism<bold>.</bold> Cellular polyamines (spermidine and spermine) are tightly regulated polycations that regulate cell growth and proliferation<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Cellular polyamine synthesis is up-regulated during bacterial infections and inflammation<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. During such inflammatory stress, the catabolic enzyme spermidine/spermine <italic>N</italic>1-acetyltransferase (SSAT) is induced by TNFα. Induced SSAT increases polyamide catabolism and the exit of intracellular polyamine metabolites into the circulation. Such decreases in the concentration of intracellular polyamines lead to slower cell growth rates allowing for potential cell repair or increased apoptosis during inflammation<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>.</p>
              <p id="Par16">Further, we demonstrate that increased procalcitonin is associated with increases in phosphatidylethanolamines and decreases in lysophosphatidylcholine. Phosphatidyl-ethanolamines are present on microparticle surfaces of the endothelium and white blood cells are liberated from endothelial cells following exposure to oxidative stress and found in plasma following experimental sepsis<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. Lysophosphatidylcholines are proinflammatory lipids that activate monocytes, macrophages and T cells. Lower levels of lysophosphatidylcholines are reflective of endothelial dysfunction and are associated with severity of community-acquired pneumonia and sepsis<sup><xref ref-type="bibr" rid="CR43">43</xref>–<xref ref-type="bibr" rid="CR45">45</xref></sup>. The increased phosphatidylethanolamines and decreased lysophosphatidylcholines with increased procalcitonin observed in our study may reflect endothelial dysfunction from inflammation or direct procalcitonin exposure and indicate dysregulation of the immune response in the setting of more intense inflammation, respectively<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>.</p>
              <p id="Par17">The methodology in our study has multiple strengths. Linear mixed-effects models are vigorous analysis tools for metabolomics studies with repeated time points and multiple clinical variables<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Our approach allows for a focus on metabolites that change relative to procalcitonin rather than simply change with the course of critical illness or trial intervention<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. To limit false positive observations, we conservatively adjusted our mixed-effects significance threshold to account for 983 multiple comparisons. The use of the GGM identification algorithm enhances our association analyses<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Further, prior studies show the importance of procalcitonin to the response to severe critical illness which increases the relevance and biological plausibility of our observations<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>.</p>
              <p id="Par18">Our study does have potential limitations. Despite multivariable adjustment, our use of nonrandomized comparisons is subject to bias as subjects with increases in procalcitonin may systematically differ. We performed a post-hoc analysis of plasma samples with correction for multiple testing. Thus, our finding should be considered hypothesis generating. Our study population is heterogenous and increased procalcitonin may be present for different reasons. Further, our study of White critically ill subjects from a single large academic medical center may have limited generalizability. Finally, while the highlighted metabolites have known functional and biological relevance, the clinical significance of a change in metabolite abundance may be unclear.</p>
              <p id="Par19">Taken together, our data indicate that inflammation is associated with alteration of energy utilization by specific metabolic pathways in critical illness. Early critical illness represents a state of nutrient deprivation, oxidative stress and mitochondrial dysfunction which compromise tissue metabolic needs. Circulating metabolites provide an assessment of internal energy states and energy substrate selection. Our findings provide convergent evidence that procalcitonin related inflammation alters mitochondrial bioenergetics. Identifying circulating metabolic information over time is a first step towards understanding the dynamics of energy utilization in critical illness and the metabolomic effects of inflammation.</p>
            </sec>
            <sec id="Sec7">
              <title>Methods</title>
              <p id="Par20">Detailed trial and metabolomics methods are presented in Supplementary Methods. Briefly, the VITdAL-ICU trial (NCT01130181) randomized 475 critically ill adult subjects to vitamin D<sub>3</sub> or placebo once at a dose of 540,000 IU followed by 90,000 IU monthly<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. The primary trial outcome was hospital length of stay. Whole blood was collected at randomization (day 0), day 3 and day 7. Frozen plasma was available for analysis in 453 trial subjects. We excluded 9 subjects who did not have serum procalcitonin measured at day 0 and 25 subjects who did not have 25(OH)D measured at day 3.</p>
              <p id="Par21">This study was performed in accordance with the Declaration of Helsinki. At VITdAL-ICU trial enrollment, written informed consent was obtained, if possible, directly from the patient or from a legal surrogate. Consent included permission for plasma specimens to be saved for future research studies. The post-hoc metabolomics study protocol was granted approval by the Mass General Brigham Human Research Committee at the Brigham and Women’s Hospital (Protocol # 2015P002766).</p>
              <p id="Par22">Metabolomics data was generated on a total of 1187 plasma samples from 419 subjects at day 0, 401 subjects at day 3 and 367 subjects at day 7 were analyzed using four ultra high-performance liquid chromatography/tandem accurate mass spectrometry methods by Metabolon, Inc. in 2017<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Metabolomic profiling identified 983 plasma metabolites. Individual metabolite raw area count data was normalized, underwent cube root transformation and then Pareto scaling to generate abundance data that were on the same scale and followed an approximate normal distribution.</p>
              <p id="Par23">Our exposure of interest was the individual metabolite abundance. Our primary outcome was serum procalcitonin measured at the same time as the individual metabolite. The procalcitonin level of &lt; 0.5 μg/L was assigned as a cut point indicating severe systemic inflammation<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. Study sample size was determined utilizing equations for longitudinal studies with a continuous response<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. We aimed to detect an absolute change in the mean response of procalcitonin of 0.5 μg/L over seven days. We determined the within-subject variability of procalcitonin was 4.1 and the between-subject variability in the rate of change of procalcitonin was 2.0. We utilized an FDR corrected alpha of 0.013, a power of 80%, and three repeated measurements of procalcitonin over seven days. To achieve 80% power, our study requires a study sample of 325 patients.</p>
              <p id="Par24">For univariate analysis of day 0 data, Student’s t test was used to identify metabolites that are associated with a dichotomized procalcitonin measure (procalcitonin &lt; 0.5 μg/L versus procalcitonin ≥ 0.5 μg/L) applying a false discovery rate adjusted p-value (q-value) threshold of 0.05 using MetaboAnalyst<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Day 0 data were also analyzed using orthogonal partial least square-discriminant analysis (OPLS-DA), a supervised method to assess the significance of classification discrimination (SIMCA 15.0 Umetrics, Umea, Sweden). We performed permutation testing to validate the OPLS-DA model. We employed sevenfold cross-validation analysis of variance (CV-ANOVA) to determine OPLS-DA model significance. A Receiver Operating Characteristic curve was calculated from class-belonging values predicted by the OPLS-DA model. We produced a misclassification table of the proportion of correctly classified observations (procalcitonin &lt; 0.5 μg/L vs procalcitonin ≥ 0.5 μg/L) in the day 0 data.</p>
              <p id="Par25">For repeated measures data in 419 subjects, the association between relative abundance of individual metabolites (as a continuous exposure) and procalcitonin levels (outcome) at day 0, 3 and 7 were determined utilizing linear mixed-effects models correcting for age, sex, baseline 25(OH)D, absolute increase in 25(OH)D at day 3, SAPS II, plasma day, admission diagnosis and individual subject (as the random-intercept). To identify all significant mixed-effects associations we utilized multiple testing correction based on the Benjamini–Hochberg procedure to adjust the false discovery rate (FDR) to 0.05<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. All mixed-effects models were analyzed using STATA 16.1MP (College Station, TX). We employed rain plots to visualize effect size and significance relative to procalcitonin levels<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Rain plots were produced based on hierarchical clustering in R-3.6.2.</p>
              <p id="Par26">To identify procalcitonin-specific modules from metabolite abundance data, we applied Gaussian graphical models (GGMs) using the metabolomic data from day 0 using the GeneNet R package, version 1.2.13 in R-3.6.2<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Modules are identified by reconstruction of pathway reactions derived from metabolomics data. GGMs are determined utilizing partial pairwise Pearson correlation coefficients following the removal of the effects of all other metabolites and covariates<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. We inferred a procalcitonin-specific network (procalcitonin &lt; 0.5 vs ≥ 0.5 μg/L) for relative metabolite abundance. We included age, sex, SAPS II, admission diagnosis, and baseline 25(OH)D as covariates into the model. Edges between metabolites were allotted if both their Pearson correlations and partial correlations remained statistically significant at a q-value threshold of 0.05<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>.</p>
              <p id="Par27">We finally evaluated a potential mediating effect of bilirubin, age or body mass index on the association between procalcitonin and individual metabolite abundance adjusted for age, sex, baseline 25(OH)D, SAPS II and admission diagnosis. Analyses were performed on each of the 983 metabolites at day 0 using the R package mediation<sup><xref ref-type="bibr" rid="CR54">54</xref></sup> to obtain bootstrap p-values (N = 2000 samples) for the mediation effect of age or for bilirubin. Significant mediation was present if the p-value was &lt; 0.01 and if ≥ 10% of the association was mediated through bilirubin levels, age or body mass index<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup>.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Information</title>
              <sec id="Sec8">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="41598_2021_2679_MOESM1_ESM.pdf">
                      <caption>
                        <p>Supplementary Legends.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM2">
                    <media xlink:href="41598_2021_2679_MOESM2_ESM.pdf">
                      <caption>
                        <p>Supplementary Tables.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM3">
                    <media xlink:href="41598_2021_2679_MOESM3_ESM.xlsx">
                      <caption>
                        <p>Dataset S1.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM4">
                    <media xlink:href="41598_2021_2679_MOESM4_ESM.xlsx">
                      <caption>
                        <p>Dataset S2.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM5">
                    <media xlink:href="41598_2021_2679_MOESM5_ESM.xlsx">
                      <caption>
                        <p>Dataset S3.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM6">
                    <media xlink:href="41598_2021_2679_MOESM6_ESM.xlsx">
                      <caption>
                        <p>Dataset S4.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM7">
                    <media xlink:href="41598_2021_2679_MOESM7_ESM.pdf">
                      <caption>
                        <p>Supplementary Figure 1.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM8">
                    <media xlink:href="41598_2021_2679_MOESM8_ESM.pdf">
                      <caption>
                        <p>Supplementary Information.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher's note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <sec>
              <title>Supplementary Information</title>
              <p>The online version contains supplementary material available at 10.1038/s41598-021-02679-0.</p>
            </sec>
            <ack>
              <title>Acknowledgements</title>
              <p>This article is dedicated to the memory of our dear friend and colleague Nathan Edward Hellman, MD, PhD.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>H.K.: Conceptualization, methodology, formal analysis, investigation, data curation, writing—original draft, writing—review &amp; editing, visualization. K.A.: Conceptualization, methodology, investigation, resources, data curation, writing—original draft, writing—review &amp; editing, funding acquisition. J.L.-S.: Conceptualization, methodology, formal analysis, investigation, resources, data curation, writing—original draft, writing—review &amp; editing. K.C.: Conceptualization, methodology, software, formal analysis, investigation, resources, data curation, writing—original draft, writing—review &amp; editing, visualization, supervision, project administration, funding acquisition.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>This work was supported by the National Institutes of Health [R01 GM115774]. The VITdAL-ICU trial was supported by the European Society for Clinical Nutrition and Metabolism (ESPEN), a research grant including provision of study medication from Fresenius Kabi (Germany), and the Austrian National Bank (Jubiläumsfonds, Project Nr. 14143).</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>All data generated or analysed during this study are included in this published article (and its Supplementary Information files).</p>
            </notes>
            <notes id="FPar1" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par28">Dr. Amrein reports receiving lecture fees from Fresenius Kabi. No other financial or other relationships exist that might lead to a conflict of interest.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Maruna</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Nedelnikova</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Gurlich</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Physiology and genetics of procalcitonin</article-title>
                  <source>Physiol. Res.</source>
                  <year>2000</year>
                  <volume>49</volume>
                  <issue>Suppl 1</issue>
                  <fpage>S57</fpage>
                  <lpage>61</lpage>
                  <?supplied-pmid 10984072?>
                  <pub-id pub-id-type="pmid">10984072</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Assicot</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>High serum procalcitonin concentrations in patients with sepsis and infection</article-title>
                  <source>Lancet</source>
                  <year>1993</year>
                  <volume>341</volume>
                  <fpage>515</fpage>
                  <lpage>518</lpage>
                  <pub-id pub-id-type="doi">10.1016/0140-6736(93)90277-n</pub-id>
                  <?supplied-pmid 8094770?>
                  <pub-id pub-id-type="pmid">8094770</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Christ-Crain</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Muller</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Biomarkers in respiratory tract infections: Diagnostic guides to antibiotic prescription, prognostic markers and mediators</article-title>
                  <source>Eur. Respir. J.</source>
                  <year>2007</year>
                  <volume>30</volume>
                  <fpage>556</fpage>
                  <lpage>573</lpage>
                  <pub-id pub-id-type="doi">10.1183/09031936.00166106</pub-id>
                  <?supplied-pmid 17766633?>
                  <pub-id pub-id-type="pmid">17766633</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Muller</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis</article-title>
                  <source>J. Clin. Endocrinol. Metab.</source>
                  <year>2001</year>
                  <volume>86</volume>
                  <fpage>396</fpage>
                  <lpage>404</lpage>
                  <pub-id pub-id-type="doi">10.1210/jcem.86.1.7089</pub-id>
                  <?supplied-pmid 11232031?>
                  <pub-id pub-id-type="pmid">11232031</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mitaka</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome</article-title>
                  <source>Clin. Chim. Acta Int. J. Clin. Chem.</source>
                  <year>2005</year>
                  <volume>351</volume>
                  <fpage>17</fpage>
                  <lpage>29</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cccn.2004.08.018</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hu</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Han</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Pei</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Yin</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>X</given-names>
                    </name>
                  </person-group>
                  <article-title>Procalcitonin levels in COVID-19 patients</article-title>
                  <source>Int. J. Antimicrob. Agents</source>
                  <year>2020</year>
                  <volume>56</volume>
                  <fpage>106051</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106051</pub-id>
                  <?supplied-pmid 32534186?>
                  <pub-id pub-id-type="pmid">32534186</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Whang</surname>
                      <given-names>KT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Procalcitonin and proinflammatory cytokine interactions in sepsis</article-title>
                  <source>Shock</source>
                  <year>2000</year>
                  <volume>14</volume>
                  <fpage>73</fpage>
                  <lpage>78</lpage>
                  <pub-id pub-id-type="doi">10.1097/00024382-200014010-00013</pub-id>
                  <?supplied-pmid 10909897?>
                  <pub-id pub-id-type="pmid">10909897</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wei</surname>
                      <given-names>JX</given-names>
                    </name>
                    <name>
                      <surname>Verity</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Garle</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mahajan</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>V</given-names>
                    </name>
                  </person-group>
                  <article-title>Examination of the effect of procalcitonin on human leucocytes and the porcine isolated coronary artery</article-title>
                  <source>Br. J. Anaesth.</source>
                  <year>2008</year>
                  <volume>100</volume>
                  <fpage>612</fpage>
                  <lpage>621</lpage>
                  <pub-id pub-id-type="doi">10.1093/bja/aen073</pub-id>
                  <?supplied-pmid 18385261?>
                  <pub-id pub-id-type="pmid">18385261</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wagner</surname>
                      <given-names>NM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Procalcitonin impairs endothelial cell function and viability</article-title>
                  <source>Anesth. Analg.</source>
                  <year>2017</year>
                  <volume>124</volume>
                  <fpage>836</fpage>
                  <lpage>845</lpage>
                  <pub-id pub-id-type="doi">10.1213/ANE.0000000000001574</pub-id>
                  <?supplied-pmid 27655274?>
                  <pub-id pub-id-type="pmid">27655274</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sauer</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Doss</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ehler</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Mencke</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Wagner</surname>
                      <given-names>NM</given-names>
                    </name>
                  </person-group>
                  <article-title>Procalcitonin impairs liver cell viability and function in vitro: A potential new mechanism of liver dysfunction and failure during sepsis?</article-title>
                  <source>Biomed. Res. Int.</source>
                  <year>2017</year>
                  <volume>2017</volume>
                  <fpage>6130725</fpage>
                  <pub-id pub-id-type="doi">10.1155/2017/6130725</pub-id>
                  <?supplied-pmid 28255555?>
                  <pub-id pub-id-type="pmid">28255555</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tavares</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Minano</surname>
                      <given-names>FJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: Neuroendocrine and systemic studies</article-title>
                  <source>Clin. Sci. (Lond.)</source>
                  <year>2010</year>
                  <volume>119</volume>
                  <fpage>519</fpage>
                  <lpage>534</lpage>
                  <pub-id pub-id-type="doi">10.1042/CS20100007</pub-id>
                  <pub-id pub-id-type="pmid">20569200</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wernerman</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Metabolic support in the critically ill: A consensus of 19</article-title>
                  <source>Crit. Care</source>
                  <year>2019</year>
                  <volume>23</volume>
                  <fpage>318</fpage>
                  <pub-id pub-id-type="doi">10.1186/s13054-019-2597-0</pub-id>
                  <?supplied-pmid 31533772?>
                  <pub-id pub-id-type="pmid">31533772</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Langley</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>An integrated clinico-metabolomic model improves prediction of death in sepsis</article-title>
                  <source>Sci. Transl. Med.</source>
                  <year>2013</year>
                  <volume>5</volume>
                  <fpage>195ra195</fpage>
                  <pub-id pub-id-type="doi">10.1126/scitranslmed.3005893</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Amrein</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Lasky-Su</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Dobnig</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Christopher</surname>
                      <given-names>KB</given-names>
                    </name>
                  </person-group>
                  <article-title>Metabolomic basis for response to high dose vitamin D in critical illness</article-title>
                  <source>Clin. Nutr.</source>
                  <year>2021</year>
                  <volume>40</volume>
                  <fpage>2053</fpage>
                  <lpage>2060</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.clnu.2020.09.028</pub-id>
                  <?supplied-pmid 33087250?>
                  <pub-id pub-id-type="pmid">33087250</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Amrein</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: The VITdAL-ICU randomized clinical trial</article-title>
                  <source>JAMA</source>
                  <year>2014</year>
                  <volume>312</volume>
                  <fpage>1520</fpage>
                  <lpage>1530</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2014.13204</pub-id>
                  <?supplied-pmid 25268295?>
                  <pub-id pub-id-type="pmid">25268295</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Benjamini</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Hochberg</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Controlling for false discovery rate: A practical and powerful approach to multiple testing</article-title>
                  <source>J. R. Stat. Soc. Ser. B (Methodol.)</source>
                  <year>1995</year>
                  <volume>57</volume>
                  <fpage>289</fpage>
                  <lpage>300</lpage>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Koves</surname>
                      <given-names>TR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance</article-title>
                  <source>Cell Metab.</source>
                  <year>2008</year>
                  <volume>7</volume>
                  <fpage>45</fpage>
                  <lpage>56</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cmet.2007.10.013</pub-id>
                  <?supplied-pmid 18177724?>
                  <pub-id pub-id-type="pmid">18177724</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wanders</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Komen</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kemp</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans</article-title>
                  <source>FEBS J.</source>
                  <year>2011</year>
                  <volume>278</volume>
                  <fpage>182</fpage>
                  <lpage>194</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1742-4658.2010.07947.x</pub-id>
                  <?supplied-pmid 21156023?>
                  <pub-id pub-id-type="pmid">21156023</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kalsotra</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes</article-title>
                  <source>Arch. Biochem. Biophys.</source>
                  <year>2007</year>
                  <volume>461</volume>
                  <fpage>104</fpage>
                  <lpage>112</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.abb.2007.02.027</pub-id>
                  <?supplied-pmid 17418803?>
                  <pub-id pub-id-type="pmid">17418803</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kemp</surname>
                      <given-names>PR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Metabolic profiling shows pre-existing mitochondrial dysfunction contributes to muscle loss in a model of ICU-acquired weakness</article-title>
                  <source>J. Cachexia Sarcopenia Muscle.</source>
                  <year>2020</year>
                  <pub-id pub-id-type="doi">10.1002/jcsm.12597</pub-id>
                  <?supplied-pmid 32677363?>
                  <pub-id pub-id-type="pmid">32677363</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nalos</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Transcriptional reprogramming of metabolic pathways in critically ill patients</article-title>
                  <source>Intensive Care Med. Exp.</source>
                  <year>2016</year>
                  <volume>4</volume>
                  <fpage>21</fpage>
                  <pub-id pub-id-type="doi">10.1186/s40635-016-0094-1</pub-id>
                  <?supplied-pmid 27387528?>
                  <pub-id pub-id-type="pmid">27387528</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vico</surname>
                      <given-names>TA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mitochondrial bioenergetics links inflammation and cardiac contractility in endotoxemia</article-title>
                  <source>Basic Res. Cardiol.</source>
                  <year>2019</year>
                  <volume>114</volume>
                  <fpage>38</fpage>
                  <pub-id pub-id-type="doi">10.1007/s00395-019-0745-y</pub-id>
                  <?supplied-pmid 31428876?>
                  <pub-id pub-id-type="pmid">31428876</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meisner</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Muller</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Khakpour</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Toegel</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Redl</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Induction of procalcitonin and proinflammatory cytokines in an anhepatic baboon endotoxin shock model</article-title>
                  <source>Shock</source>
                  <year>2003</year>
                  <volume>19</volume>
                  <fpage>187</fpage>
                  <lpage>190</lpage>
                  <pub-id pub-id-type="doi">10.1097/00024382-200302000-00017</pub-id>
                  <?supplied-pmid 12578130?>
                  <pub-id pub-id-type="pmid">12578130</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Neinast</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Murashige</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Arany</surname>
                      <given-names>Z</given-names>
                    </name>
                  </person-group>
                  <article-title>Branched chain amino acids</article-title>
                  <source>Annu. Rev. Physiol.</source>
                  <year>2019</year>
                  <volume>81</volume>
                  <fpage>139</fpage>
                  <lpage>164</lpage>
                  <pub-id pub-id-type="doi">10.1146/annurev-physiol-020518-114455</pub-id>
                  <?supplied-pmid 30485760?>
                  <pub-id pub-id-type="pmid">30485760</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hasselgren</surname>
                      <given-names>PO</given-names>
                    </name>
                    <name>
                      <surname>Pedersen</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Sax</surname>
                      <given-names>HC</given-names>
                    </name>
                    <name>
                      <surname>Warner</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Fischer</surname>
                      <given-names>JE</given-names>
                    </name>
                  </person-group>
                  <article-title>Current concepts of protein turnover and amino acid transport in liver and skeletal muscle during sepsis</article-title>
                  <source>Arch. Surg.</source>
                  <year>1988</year>
                  <volume>123</volume>
                  <fpage>992</fpage>
                  <lpage>999</lpage>
                  <pub-id pub-id-type="doi">10.1001/archsurg.1988.01400320078016</pub-id>
                  <?supplied-pmid 3293552?>
                  <pub-id pub-id-type="pmid">3293552</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Harris</surname>
                      <given-names>RA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Regulation of the branched-chain alpha-ketoacid dehydrogenase and elucidation of a molecular basis for maple syrup urine disease</article-title>
                  <source>Adv. Enzyme Regul.</source>
                  <year>1990</year>
                  <volume>30</volume>
                  <fpage>245</fpage>
                  <lpage>263</lpage>
                  <pub-id pub-id-type="doi">10.1016/0065-2571(90)90021-s</pub-id>
                  <?supplied-pmid 2403034?>
                  <pub-id pub-id-type="pmid">2403034</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kobayashi</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hepatic branched-chain alpha-keto acid dehydrogenase complex in female rats: Activation by exercise and starvation</article-title>
                  <source>J. Nutr. Sci. Vitaminol. (Tokyo)</source>
                  <year>1999</year>
                  <volume>45</volume>
                  <fpage>303</fpage>
                  <lpage>309</lpage>
                  <pub-id pub-id-type="doi">10.3177/jnsv.45.303</pub-id>
                  <pub-id pub-id-type="pmid">10524349</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xu</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mechanism of activation of branched-chain alpha-keto acid dehydrogenase complex by exercise</article-title>
                  <source>Biochem. Biophys. Res. Commun.</source>
                  <year>2001</year>
                  <volume>287</volume>
                  <fpage>752</fpage>
                  <lpage>756</lpage>
                  <pub-id pub-id-type="doi">10.1006/bbrc.2001.5647</pub-id>
                  <?supplied-pmid 11563860?>
                  <pub-id pub-id-type="pmid">11563860</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shiraki</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Activation of hepatic branched-chain alpha-keto acid dehydrogenase complex by tumor necrosis factor-alpha in rats</article-title>
                  <source>Biochem. Biophys. Res. Commun.</source>
                  <year>2005</year>
                  <volume>328</volume>
                  <fpage>973</fpage>
                  <lpage>978</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.bbrc.2005.01.047</pub-id>
                  <?supplied-pmid 15707973?>
                  <pub-id pub-id-type="pmid">15707973</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nawabi</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Block</surname>
                      <given-names>KP</given-names>
                    </name>
                    <name>
                      <surname>Chakrabarti</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Buse</surname>
                      <given-names>MG</given-names>
                    </name>
                  </person-group>
                  <article-title>Administration of endotoxin, tumor necrosis factor, or interleukin 1 to rats activates skeletal muscle branched-chain alpha-keto acid dehydrogenase</article-title>
                  <source>J. Clin. Investig.</source>
                  <year>1990</year>
                  <volume>85</volume>
                  <fpage>256</fpage>
                  <lpage>263</lpage>
                  <pub-id pub-id-type="doi">10.1172/JCI114421</pub-id>
                  <?supplied-pmid 2404025?>
                  <pub-id pub-id-type="pmid">2404025</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rooyackers</surname>
                      <given-names>OE</given-names>
                    </name>
                    <name>
                      <surname>Senden</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Soeters</surname>
                      <given-names>PB</given-names>
                    </name>
                    <name>
                      <surname>Saris</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Wagenmakers</surname>
                      <given-names>AJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Prolonged activation of the branched-chain alpha-keto acid dehydrogenase complex in muscle of zymosan treated rats</article-title>
                  <source>Eur. J. Clin. Investig.</source>
                  <year>1995</year>
                  <volume>25</volume>
                  <fpage>548</fpage>
                  <lpage>552</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1365-2362.1995.tb01744.x</pub-id>
                  <pub-id pub-id-type="pmid">7589009</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Overmyer</surname>
                      <given-names>KA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Maximal oxidative capacity during exercise is associated with skeletal muscle fuel selection and dynamic changes in mitochondrial protein acetylation</article-title>
                  <source>Cell Metab.</source>
                  <year>2015</year>
                  <volume>21</volume>
                  <fpage>468</fpage>
                  <lpage>478</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cmet.2015.02.007</pub-id>
                  <?supplied-pmid 25738461?>
                  <pub-id pub-id-type="pmid">25738461</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gamrin</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Essen</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Forsberg</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Hultman</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Wernerman</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>A descriptive study of skeletal muscle metabolism in critically ill patients: Free amino acids, energy-rich phosphates, protein, nucleic acids, fat, water, and electrolytes</article-title>
                  <source>Crit. Care Med.</source>
                  <year>1996</year>
                  <volume>24</volume>
                  <fpage>575</fpage>
                  <lpage>583</lpage>
                  <pub-id pub-id-type="doi">10.1097/00003246-199604000-00005</pub-id>
                  <?supplied-pmid 8612406?>
                  <pub-id pub-id-type="pmid">8612406</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Su</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Dynamic changes in amino acid concentration profiles in patients with sepsis</article-title>
                  <source>PLoS One</source>
                  <year>2015</year>
                  <volume>10</volume>
                  <fpage>e0121933</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0121933</pub-id>
                  <?supplied-pmid 25849571?>
                  <pub-id pub-id-type="pmid">25849571</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Newgard</surname>
                      <given-names>CB</given-names>
                    </name>
                  </person-group>
                  <article-title>Interplay between lipids and branched-chain amino acids in development of insulin resistance</article-title>
                  <source>Cell Metab.</source>
                  <year>2012</year>
                  <volume>15</volume>
                  <fpage>606</fpage>
                  <lpage>614</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cmet.2012.01.024</pub-id>
                  <?supplied-pmid 22560213?>
                  <pub-id pub-id-type="pmid">22560213</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Newgard</surname>
                      <given-names>CB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance</article-title>
                  <source>Cell Metab.</source>
                  <year>2009</year>
                  <volume>9</volume>
                  <fpage>311</fpage>
                  <lpage>326</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cmet.2009.02.002</pub-id>
                  <?supplied-pmid 19356713?>
                  <pub-id pub-id-type="pmid">19356713</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Calvano</surname>
                      <given-names>SE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A network-based analysis of systemic inflammation in humans</article-title>
                  <source>Nature</source>
                  <year>2005</year>
                  <volume>437</volume>
                  <fpage>1032</fpage>
                  <lpage>1037</lpage>
                  <pub-id pub-id-type="doi">10.1038/nature03985</pub-id>
                  <?supplied-pmid 16136080?>
                  <pub-id pub-id-type="pmid">16136080</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mandal</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mandal</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Johansson</surname>
                      <given-names>HE</given-names>
                    </name>
                    <name>
                      <surname>Orjalo</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>MH</given-names>
                    </name>
                  </person-group>
                  <article-title>Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells</article-title>
                  <source>Proc. Natl. Acad. Sci. U. S. A.</source>
                  <year>2013</year>
                  <volume>110</volume>
                  <fpage>2169</fpage>
                  <lpage>2174</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.1219002110</pub-id>
                  <?supplied-pmid 23345430?>
                  <pub-id pub-id-type="pmid">23345430</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hardbower</surname>
                      <given-names>DM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ornithine decarboxylase regulates M1 macrophage activation and mucosal inflammation via histone modifications</article-title>
                  <source>Proc. Natl. Acad. Sci. U. S. A.</source>
                  <year>2017</year>
                  <volume>114</volume>
                  <fpage>E751</fpage>
                  <lpage>E760</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.1614958114</pub-id>
                  <?supplied-pmid 28096401?>
                  <pub-id pub-id-type="pmid">28096401</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Babbar</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Murray-Stewart</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Casero</surname>
                      <given-names>RA</given-names>
                      <suffix>Jr</suffix>
                    </name>
                  </person-group>
                  <article-title>Inflammation and polyamine catabolism: The good, the bad and the ugly</article-title>
                  <source>Biochem. Soc. Trans.</source>
                  <year>2007</year>
                  <volume>35</volume>
                  <fpage>300</fpage>
                  <lpage>304</lpage>
                  <pub-id pub-id-type="doi">10.1042/BST0350300</pub-id>
                  <?supplied-pmid 17371265?>
                  <pub-id pub-id-type="pmid">17371265</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Colombo</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phospholipidome of endothelial cells shows a different adaptation response upon oxidative, glycative and lipoxidative stress</article-title>
                  <source>Sci. Rep.</source>
                  <year>2018</year>
                  <volume>8</volume>
                  <fpage>12365</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41598-018-30695-0</pub-id>
                  <?supplied-pmid 30120318?>
                  <pub-id pub-id-type="pmid">30120318</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ahn</surname>
                      <given-names>WG</given-names>
                    </name>
                    <name>
                      <surname>Jung</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Song</surname>
                      <given-names>DK</given-names>
                    </name>
                  </person-group>
                  <article-title>Lipidomic analysis of plasma lipids composition changes in septic mice</article-title>
                  <source>Korean J. Physiol. Pharmacol.</source>
                  <year>2018</year>
                  <volume>22</volume>
                  <fpage>399</fpage>
                  <lpage>408</lpage>
                  <pub-id pub-id-type="doi">10.4196/kjpp.2018.22.4.399</pub-id>
                  <?supplied-pmid 29962854?>
                  <pub-id pub-id-type="pmid">29962854</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Arshad</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Decreased plasma phospholipid concentrations and increased acid sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia</article-title>
                  <source>J. Transl. Med.</source>
                  <year>2019</year>
                  <volume>17</volume>
                  <fpage>365</fpage>
                  <pub-id pub-id-type="doi">10.1186/s12967-019-2112-z</pub-id>
                  <?supplied-pmid 31711507?>
                  <pub-id pub-id-type="pmid">31711507</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ahn</surname>
                      <given-names>WG</given-names>
                    </name>
                    <name>
                      <surname>Jung</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Kwon</surname>
                      <given-names>HY</given-names>
                    </name>
                    <name>
                      <surname>Song</surname>
                      <given-names>DK</given-names>
                    </name>
                  </person-group>
                  <article-title>Alteration of lysophosphatidylcholine-related metabolic parameters in the plasma of mice with experimental sepsis</article-title>
                  <source>Inflammation</source>
                  <year>2017</year>
                  <volume>40</volume>
                  <fpage>537</fpage>
                  <lpage>545</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10753-016-0500-6</pub-id>
                  <?supplied-pmid 28028754?>
                  <pub-id pub-id-type="pmid">28028754</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van Nieuw Amerongen</surname>
                      <given-names>GP</given-names>
                    </name>
                    <name>
                      <surname>Vermeer</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>van Hinsbergh</surname>
                      <given-names>VW</given-names>
                    </name>
                  </person-group>
                  <article-title>Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction</article-title>
                  <source>Arterioscler. Thromb. Vasc. Biol.</source>
                  <year>2000</year>
                  <volume>20</volume>
                  <fpage>E127</fpage>
                  <lpage>133</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.atv.20.12.e127</pub-id>
                  <?supplied-pmid 11116077?>
                  <pub-id pub-id-type="pmid">11116077</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Oberg</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Mahoney</surname>
                      <given-names>DW</given-names>
                    </name>
                  </person-group>
                  <article-title>Linear mixed effects models</article-title>
                  <source>Methods Mol. Biol.</source>
                  <year>2007</year>
                  <volume>404</volume>
                  <fpage>213</fpage>
                  <lpage>234</lpage>
                  <pub-id pub-id-type="doi">10.1007/978-1-59745-530-5_11</pub-id>
                  <?supplied-pmid 18450052?>
                  <pub-id pub-id-type="pmid">18450052</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kelly</surname>
                      <given-names>RS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Integration of metabolomic and transcriptomic networks in pregnant women reveals biological pathways and predictive signatures associated with preeclampsia</article-title>
                  <source>Metabolomics</source>
                  <year>2017</year>
                  <pub-id pub-id-type="doi">10.1007/s11306-016-1149-8</pub-id>
                  <?supplied-pmid 30473646?>
                  <pub-id pub-id-type="pmid">30473646</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Do</surname>
                      <given-names>KT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phenotype-driven identification of modules in a hierarchical map of multifluid metabolic correlations</article-title>
                  <source>NPJ Syst. Biol. Appl.</source>
                  <year>2017</year>
                  <volume>3</volume>
                  <fpage>28</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41540-017-0029-9</pub-id>
                  <?supplied-pmid 28948040?>
                  <pub-id pub-id-type="pmid">28948040</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Harbarth</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis</article-title>
                  <source>Am. J. Respir. Crit. Care Med.</source>
                  <year>2001</year>
                  <volume>164</volume>
                  <fpage>396</fpage>
                  <lpage>402</lpage>
                  <pub-id pub-id-type="doi">10.1164/ajrccm.164.3.2009052</pub-id>
                  <?supplied-pmid 11500339?>
                  <pub-id pub-id-type="pmid">11500339</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <mixed-citation publication-type="other">FitzMaurice, G. M., Laird, N. M. &amp; Ware, J. H. <italic>Applied Longitudinal Analysis</italic>. 594–595 (Wiley, 2011).</mixed-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Benjamini</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Yekutieli</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>The control of the false discovery rate in multiple testing under dependency</article-title>
                  <source>Ann. Stat.</source>
                  <year>2001</year>
                  <volume>29</volume>
                  <fpage>1165</fpage>
                  <lpage>1188</lpage>
                  <pub-id pub-id-type="doi">10.1214/aos/1013699998</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Henglin</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A single visualization technique for displaying multiple metabolite-phenotype associations</article-title>
                  <source>Metabolites</source>
                  <year>2019</year>
                  <pub-id pub-id-type="doi">10.3390/metabo9070128</pub-id>
                  <?supplied-pmid 31336989?>
                  <pub-id pub-id-type="pmid">31336989</pub-id>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krumsiek</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Suhre</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Illig</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Adamski</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Theis</surname>
                      <given-names>FJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Gaussian graphical modeling reconstructs pathway reactions from high-throughput metabolomics data</article-title>
                  <source>BMC Syst. Biol.</source>
                  <year>2011</year>
                  <volume>5</volume>
                  <fpage>21</fpage>
                  <pub-id pub-id-type="doi">10.1186/1752-0509-5-21</pub-id>
                  <?supplied-pmid 21281499?>
                  <pub-id pub-id-type="pmid">21281499</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dustin</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Yamamoto</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Hirose</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Keele</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Imai</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>mediation: R package for causal mediation analysis</article-title>
                  <source>J. Stat. Softw.</source>
                  <year>2014</year>
                  <volume>59</volume>
                  <fpage>1</fpage>
                  <lpage>38</lpage>
                  <pub-id pub-id-type="pmid">26917999</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chary</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Amrein</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Lasky-Su</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Dobnig</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Christopher</surname>
                      <given-names>KB</given-names>
                    </name>
                  </person-group>
                  <article-title>The sex-specific metabolic response to critical illness: A post-hoc metabolomics study of the VITdAL-ICU trial</article-title>
                  <source>Sci. Rep.</source>
                  <year>2021</year>
                  <volume>11</volume>
                  <fpage>3951</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41598-021-83602-5</pub-id>
                  <pub-id pub-id-type="pmid">33597589</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
